Contract notice CN3936165 · National Blood Authority
Imported Plasma and Recombinant Products
$170m
whole-of-life value, after 1 amendment
+$89m (+111.1%) since first published at $80m
- Supplier
- Novo Nordisk Pharmaceuticals Pty Ltd ABN 40002879996
- Agency
- National Blood Authority
- Procurement method
- limited tender
- Reason given
- 10.3.d.iii. Supply by particular business: due to an absence of competition for technical reasons.
- Term
- 2023-01-01 to 2027-06-30
- Published
- 2023-02-09
- Category (UNSPSC)
- 85100000
- Agency reference
- CBP-CON-00171
Worth a closer look
Value increased after award: +111% on first published value. Agencies must publish amendments that change a contract’s value. Large increases can mean the original scope or price was understated.
Common explanations: Additional work or an extended term agreed after award. Options in the original contract that were later taken up. A correction to a value entered wrongly.
Value by financial year
The total value spread evenly from start to end date. estimate: annualised
| Financial year | Estimated amount |
|---|---|
| 2022-23 | $19m |
| 2023-24 | $38m |
| 2024-25 | $38m |
| 2025-26 | $38m |
| 2026-27 | $38m |
Published versions
Every version of this notice we have loaded. Source: AusTender OCDS API.
| Date | Version | Value |
|---|---|---|
| 2023-02-09 | original notice | $80m |
| 2026-07-16 | amendment | $115m |
| 2026-07-16 | amendment | $170m |